Addition of everolimus to trastuzumab plus vinorelbine significantly prolonged progression-free survival in patients with trastuzumab-resistant and taxane-pre-treated, Her2-positive, advanced breast cancer [47]. This evidence concerns the gene ERBB2 and breast cancer.